argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.

argenx SE

Property, Plant and Equipment

Property, Plant and Equipment %Chg

Property, Plant and Equipment Common Size

Intangible Assets

Intangible Assets %Chg

Intangible Assets Common Size

Deferred Tax Assets

Deferred Tax Assets %Chg

Deferred Tax Assets Common Size

Research and Development Incentive Receivables

Research and Development Incentive Receivables %Chg

Research and Development Incentive Receivables Common Size

Investment in Joint Venture

Investment in Joint Venture %Chg

Investment in Joint Venture Common Size

Prepaid Expenses

Prepaid Expenses %Chg

Prepaid Expenses Common Size

Other Non-Current Assets

Other Non-Current Assets %Chg

Other Non-Current Assets Common Size

Total Non-Current Assets

Total Non-Current Assets %Chg

Total Non-Current Assets Common Size

Inventories

Inventories %Chg

Inventories Common Size

Trade and Other Receivables

Trade and Other Receivables %Chg

Trade and Other Receivables Common Size

Financial Assets

Financial Assets %Chg

Financial Assets Common Size

Cash and Cash Equivalents

Cash and Cash Equivalents %Chg

Cash and Cash Equivalents Common Size

Restricted Cash - Current

Restricted Cash - Current %Chg

Restricted Cash - Current Common Size

Total Current Assets

Total Current Assets %Chg

Total Current Assets Common Size

Restricted Cash - Non-Current

Restricted Cash - Non-Current %Chg

Restricted Cash - Non-Current Common Size

Financial Assets - Non-Current

Financial Assets - Non-Current %Chg

Financial Assets - Non-Current Common Size

Total Assets

Total Assets %Chg

Total Assets Common Size

Share Capital

Share Capital %Chg

Share Capital Common Size

Share Premium

Share Premium %Chg

Share Premium Common Size

Translation Differences

Translation Differences %Chg

Translation Differences Common Size

Accumulated Losses

Accumulated Losses %Chg

Accumulated Losses Common Size

Other Reserves

Other Reserves %Chg

Other Reserves Common Size

Total Equity

Total Equity %Chg

Total Equity Common Size

Deferred Tax Liabilities

Deferred Tax Liabilities %Chg

Deferred Tax Liabilities Common Size

Provisions for Employee Benefits

Provisions for Employee Benefits %Chg

Provisions for Employee Benefits Common Size

Lease Liabilities

Lease Liabilities %Chg

Lease Liabilities Common Size

Deferred Revenue

Deferred Revenue %Chg

Deferred Revenue Common Size

Total Non-Current Liabilities

Total Non-Current Liabilities %Chg

Total Non-Current Liabilities Common Size

Trade and Other Payables

Trade and Other Payables %Chg

Trade and Other Payables Common Size

Current Tax Liabilities

Short-Term Investments

Short-Term Investments %Chg

Short-Term Investments Common Size

Total Cash and Cash Equivalents

Total Cash and Cash Equivalents %Chg

Total Cash and Cash Equivalents Common Size

Accounts Receivable

Accounts Receivable %Chg

Accounts Receivable Common Size

Other Receivables

Other Receivables %Chg

Other Receivables Common Size

Total Trade Receivables

Total Trade Receivables %Chg

Total Trade Receivables Common Size

Other Current Assets

Other Current Assets %Chg

Other Current Assets Common Size

Net Property, Plant & Equipment

Net Property, Plant & Equipment %Chg

Net Property, Plant & Equipment Common Size

Net Intangible Assets

Net Intangible Assets %Chg

Net Intangible Assets Common Size

Long-Term Investments

Long-Term Investments %Chg

Long-Term Investments Common Size

Other Long-Term Assets

Other Long-Term Assets %Chg

Other Long-Term Assets Common Size

Accounts Payable

Accounts Payable %Chg

Accounts Payable Common Size

Revenue

EBIT

EBITDA

CapEx

Net Interest Income

Assets

Adjusted EBITDA

Gross Profit

Adjusted Net Income

Net Revenue

Net Income

Average Assets

Adjusted EBIT

Adjusted Revenue

Adjusted EBT

Adjusted Funds From Operations

Assets	Jun '25	Dec '24	Jun '24	Dec '23	Jun '23	Dec '22
Cash and Cash Equivalents	2,086	1,499.9	1,438.2	2,048.8	1,110.6	800.7
Cash and Cash Equivalents
Restricted Cash - Current
Restricted Cash - Non-Current
Short-Term Investments	1,842.2	1,878.9	1,664.1	1,131	886.4	1,391.8
Financial Assets
Financial Assets - Non-Current
Total Cash and Cash Equivalents	3,928.2	3,378.8	3,102.3	3,179.8	1,997	2,192.5
Accounts Receivable	1,197.1	904.5	652.9	496.7	353.2	275.7
Trade and Other Receivables
Other Receivables	1.2	4.6	2.7	2.6	1.4	1.6
Research and Development Incentive Receivables
Total Trade Receivables	1,198.2	909.1	655.6	499.3	354.6	277.3
Inventories	340.6	407.2	326.5	310.6	201.1	228.4
Inventories
Other Current Assets	362.7	187.9	179.4	134.1	138.8	76
Prepaid Expenses
Total Current Assets	5,829.7	4,883.1	4,263.8	4,123.7	2,691.5	2,774.2
Total Current Assets
Net Property, Plant & Equipment	45.8	43.5	36.9	22.7	14.7	16.2
Property, Plant and Equipment
Net Intangible Assets	219	181.4	141.8	125.2	189.9	174.9
Intangible Assets
Long-Term Investments	10.7	9.3	6.6	9.9	12.4	1.3
Investment in Joint Venture
Other Long-Term Assets	1,070.4	1,085.2	347.5	260.9	285.3	167.6
Deferred Tax Assets
Research and Development Incentive Receivables
Prepaid Expenses
Other Non-Current Assets
Total Assets	7,175.6	6,202.5	4,796.6	4,542.5	3,193.8	3,134.3
Total Assets

Liabilities	Jun '25	Dec '24	Jun '24	Dec '23	Jun '23	Dec '22
Accounts Payable	1,016.2	650	479.8	414	310	295.7
Trade and Other Payables
Current Portion of Leases	7.6	6.5	5.9	4.6	3.2	3.4
Lease Liabilities
Unearned Revenue	—	—	—	—	—	—
Deferred Revenue
Deferred Revenue - Current
Deferred Revenue
Other Current Liabilities	18.2	13.4	13.9	4.3	4.6	3.2
Tax Liabilities
Current Tax Liabilities
Total Current Liabilities	1,041.9	669.9	499.6	423	317.8	302.3
Total Current Liabilities
Leases	35.6	32.5	28.1	15.4	8	9
Lease Liabilities
Other Long-Term Liabilities	2.4	1.8	6.6	6.6	9.9	9.3
Provisions for Employee Benefits
Deferred Tax Liabilities
Deferred Tax Liabilities
Deferred Revenue
Total Long-Term Liabilities	37.9	34.3	34.7	22	17.9	18.3
Total Non-Current Liabilities
Total Liabilities	1,079.8	704.2	534.3	445	335.7	320.6
Total Liabilities

Equity	Jun '25	Dec '24	Jun '24	Dec '23	Jun '23	Dec '22
Common Stock	7.3	7.2	7.1	7.1	6.7	6.6
Share Capital
Additional Paid-in Capital	6,025.8	5,948.9	5,747.4	5,651.5	4,374.3	4,309.9
Share Premium
Accumulated Other Comprehensive Income	133.3	126.8	128.9	131.5	130	129.3
Translation Differences
Retained Earnings	-70.6	-584.7	-1,621.2	-1,692.6	-1,653	-1,632.1
Accumulated Losses
Other Reserves
Total Common Shareholders' Equity	6,095.8	5,498.3	4,262.2	4,097.5	2,858.1	2,813.7
Total Equity
Total Shareholders' Equity	6,095.8	5,498.3	4,262.2	4,097.5	2,858.1	2,813.7
Total Liabilities and Shareholders' Equity	7,175.6	6,202.5	4,796.6	4,542.5	3,193.8	3,134.3
Total Equity and Liabilities
Total Equity and Liabilities